These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1968558)

  • 21. Early HIV infection: to treat or not to treat?
    Swart AM; Weller I; Darbyshire JH
    BMJ; 1990 Oct; 301(6756):825-6. PubMed ID: 2282416
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro.
    Sarin PS; Gallo RC; Scheer DI; Crews F; Lippa AS
    N Engl J Med; 1985 Nov; 313(20):1289-90. PubMed ID: 2414659
    [No Abstract]   [Full Text] [Related]  

  • 23. In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition.
    Diomede L; Damia G; D'Incalci M; Imperatori L; Algeri M; Modest EJ; Salmona M
    Int J Cancer; 1994 Nov; 59(4):580-1. PubMed ID: 7960229
    [No Abstract]   [Full Text] [Related]  

  • 24. [Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS].
    de Gans J; Lange JM; Derix MM; de Wolf F; Ongerboer de Visser BW; Goudsmit J
    Ned Tijdschr Geneeskd; 1988 Sep; 132(36):1656-60. PubMed ID: 3050555
    [No Abstract]   [Full Text] [Related]  

  • 25. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
    Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R
    J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1989 Nov; 262(18):2503. PubMed ID: 2509741
    [No Abstract]   [Full Text] [Related]  

  • 27. Is AL721 really a lipid fluidity modulating agent?
    Offner FA; Traill KN; Winter U; Wick G
    J Invest Dermatol; 1988 Dec; 91(6):607-8. PubMed ID: 3192959
    [No Abstract]   [Full Text] [Related]  

  • 28. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
    Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
    AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Half-dose zidovudine.
    de Truchis P; Salmon D; Matheron S; Jelasko P; Rozenbaum W; Leport C
    Lancet; 1991 May; 337(8749):1109. PubMed ID: 1673539
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical trials of zidovudine in HIV infection.
    Lancet; 1989 Aug; 2(8661):483-4. PubMed ID: 2570190
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine.
    Jacobson MA; Abrams DI; Volberding PA; Bacchetti P; Wilber J; Chaisson RE; Crowe S; Howard W; Moss A
    J Infect Dis; 1989 Jun; 159(6):1029-36. PubMed ID: 2566637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid requirements of human T lymphocytes stimulated with mitogen in serum-free medium. Membrane "fluidity" changes are an artefact of lipid (AL721) uptake by monocytes.
    Traill KN; Offner F; Winter U; Paltauf F; Wick G
    Immunobiology; 1988 Mar; 176(4-5):450-64. PubMed ID: 3292405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1H-NMR assay of phosphatidylcholine and phosphatidylethanolamine in AL721.
    Cheung AP; Olson LL
    J Pharm Biomed Anal; 1990; 8(8-12):729-34. PubMed ID: 1966071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 31P-NMR assay of phosphatidylcholine and phosphatidylethanolamine in AL721.
    Olson LL; Cheung AP
    J Pharm Biomed Anal; 1990; 8(8-12):725-8. PubMed ID: 2100614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between serum p24 antigen and the isolation of human immunodeficiency virus (HIV) from the lymphocytes of subjects with HIV infection].
    Angarano G; Fiore JR; Casalino C; Monno L; Esposito M; Pastore G
    Boll Soc Ital Biol Sper; 1988 Aug; 64(8):739-45. PubMed ID: 3214574
    [No Abstract]   [Full Text] [Related]  

  • 36. Low-dose zidovudine for AIDS.
    Sette P; Narciso P; Tozzi V; Camporiondo MP; Galgani S; Leoni GC; Tossini G; Visco G
    Lancet; 1989 May; 1(8647):1136-7. PubMed ID: 2566073
    [No Abstract]   [Full Text] [Related]  

  • 37. Statistical methods for the analysis of HIV-1 core polypeptide antigen data in clinical studies.
    Makuch RW; Parks WP
    AIDS Res Hum Retroviruses; 1988 Aug; 4(4):305-16. PubMed ID: 3061416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ddI--a good start, but still phase I.
    Fauci AS
    N Engl J Med; 1990 May; 322(19):1386-8. PubMed ID: 2109198
    [No Abstract]   [Full Text] [Related]  

  • 39. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.
    Spector SA; Kennedy C; McCutchan JA; Bozzette SA; Straube RG; Connor JD; Richman DD
    J Infect Dis; 1989 May; 159(5):822-8. PubMed ID: 2496173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatment being tested against AIDS and ARC.
    Oncology (Williston Park); 1987 Sep; 1(7):11. PubMed ID: 2856351
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.